R admission Patient informed about the nature of the study and

R admission Patient informed about the nature of the study and agreeing with its general terms and having signed the informed consent, as approved by the Research Ethics Committee of the respective center Patient eligible for coronary angiography and both radial and femoral PCI with the following pre-requisites: (a) palpable radial artery with the Allen or normal oximetry tests, (b) familiarity of the operator with the radial and femoral techniques using AngioSeal, (c) agreement of the operator to use the access route determined by the randomization process Exclusion criteria Less than 18 years of age Pregnancy Chronic use of vitamin K antagonists, direct thrombin inhibitors or oral factor Xa antagonists Hypersensitivity to antiplatelet and/or anticoagulant drugs Active bleeding or high bleeding risk (severe liver failure, active peptic ulcer, creatinine clearance < 30 mL/min, platelets count < 100,000 mm3) Uncontrolled systemic hypertension Cardiogenic shock Previous PubMed ID:https://www.ncbi.nlm.nih.gov/pubmed/23410069 myocardial revascularization surgery with 1 internal mammary or radial artery graft Documented chronic peripheral arterial insufficiency preventing the use of the femoral technique Severe concomitant disease with life expectancy below 12 months Participation in drug or device investigative clinical trials in the last 30 days Indication of elective percutaneous coronary intervention to be performed at a moment different from immediately after coronary angiography Medical, geographic or social conditions impairing participation in the study or inability to understand 1”-terphenyl tert-Butyl 3-oxa-2-azabicyclo[2.2.1]hept-5-ene-2-carboxylate 2-Chloro-4-fluoro-5-nitrobenzaldehyde and sign the informed consent termTable 3 Adjunct antithrombotic therapySite Drug Aspirin Clopidogrel Prasugrel Ticagrelor Enoxaparin 300 mg orally 600 mg Fmoc-Oic-OH orally 60 mg orally 180 mg orally 1 mg per kg SC No No No No 0.3 mg per kg IV if the last dose is 4-Bromopicolinaldehyde 8 to 12 hours 0.5 to 0.75 mg per kg IV if the last dose is >12 hours 85 UI per kg IV UFH or 60 UI per kg IV UFH if GPI is scheduled Intravenous loading dose of 0.25 mg per kg Intravenous loading dose of 25 mcg per kg 100 mg per PubMed ID:https://www.ncbi.nlm.nih.gov/pubmed/13867361 day orally 75 mg per day orally 10 mg per day orally 90 mg twice daily orally 1 mg per kg SC twice daily 100 mg per day orally, indefinitely 75 mg per day orally, 12 months 10 mg per day orally, 12 months 90 mg twice daily orally, 12 months No Emergency unit Catheter lab Coronary unit and/or ward Home use durationFondaparinux Abciximab Tirofiban2.5 mg SC No No2.5 mg/SC/day 0.125 mcg per kg per min for 12 hours, IV, without using HNF 0.15 mcg per kg per min for 12 to 18 hours, IV, without using HNFNo No NoGPI, IIb-IIIa glycoprotein receptor inhibitor; UFH; unfractionated heparin, IV, intravenous; SC subcutaneous.de Andrade et al. Trials 2013, 14:435 http://www.trialsjournal.com/content/14/1/Page 7 ofthe 30 days of evolution, with late follow-up by a visit or telephone call regarding cardiovascular death, AMI or stroke, at 12 months.Statistical analysisfemoral approach remains the preferred technique at many centers worldwide. The ARISE trial will help define the role of vascular closure devices as a bleeding avoidance strategy in patients with NSTEACS.Abbreviations ACS: Acute coronary syndrome; AMI: Acute myocardial infarction; ECG: Electrocardiogram; GPI: IIb-IIIa glycoprotein receptor inhibitor; NSTEACS: Non-ST-segment elevation acute coronary syndrome; PCI: Percutaneous coronary intervention; TIMI: Thrombosis in myocardial infarction; UFH: Unfractionated heparin; VCD: Vascular closure devices. Competing interests The authors declare that.